Please login to the form below

Not currently logged in
Email:
Password:

Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy

In 2019, Bayer bought out its private equity partner Versant Ventures and founders in BlueRock Therapeutics for $240m

The US Food and Drug Administration (FDA) has granted BlueRock Therapeutics a fast track designation for its cell therapy candidate DA01 for advanced Parkinson’s disease.

BlueRock – a Bayer subsidiary – is currently evaluating the pluripotent stem cell-derived dopaminergic neuron therapy in a phase 1 study.

This early-stage trial is set to enrol ten patients across the US and Canada, with its primary objective to assess the safety and tolerability of DA01 cell transplantation at one-year post-transplant.

As a secondary objective, BlueRock will assess the evidence of transplanted cell survival and motor  effects at one- and two-years post-transplant and evaluate the continued safety and tolerability at two years, as well as the feasibility of transplantation.

“Receiving fast track designation from the FDA is an important step, which will help us further accelerate clinical development of our DA01 cell therapy approach for Parkinson’s disease,” said Joachim Fruebis, chief development officer of BlueRock.

“This is another critical step in the BlueRock mission to create authentic cellular medicines to reverse devastating diseases, with the vision of improving the human condition,” he added.

In 2019, Bayer bought out its private equity partner Versant Ventures and founders in BlueRock Therapeutics for $240m, three years after setting up the company.

The decision gave Bayer complete control of BlueRock’s cell therapy pipeline, headed by DA01 and spanning various diseases in the neurology, cardiology and immunology categories.

BlueRock was set up in late 2016 with $225m in start-up funding from Bayer and investment firm Versant, shortly after Bayer backed gene-editing specialist Casebia via its Leaps by Bayer investment arm.

BlueRock’s induced pluripotent stem cells (iPSCs) platform is designed to encourage PSCs to differentiate into the dopaminergic neurons that are progressively destroyed in Parkinson’s disease.

The hope is that introducing these neurons into areas of the brain where neurons are depleted will lead to increased dopamine release, restoring motor function.

The company is also developing iPSCs that differentiate into microglia, oligodendrocytes and eneic neurons for neurology applications, cardiomyocytes for heart failure, as well as macrophages and T regulatory cells for immunology applications including immune tolerance, fibrosis and graft-versus-host disease (GvHD).

Article by
Lucy Parsons

20th July 2021

From: Research, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...